Ensho Therapeutics unveils new data on NSHO-101 as once-daily treatment for inflammatory bowel disease
Ensho Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing oral therapies for inflammatory diseases, has presented promising new data on NSHO-101, a novel once-daily ... Read More